ABSTRACT-The effects of (±)-2- [[[3-methyl-4-(2,2,2-trifluoroethoxy-2-pyridyljmethyl]-sulfinyl]-1H-benzimidazole (lansoprazole, AG-1749) and famotidine on various experimental ulcers in rats were compared. AG-1749 inhibited reflux esophagitis; gastric lesions induced by water-immersion stress, aspirin or ethanol; and duodenal ulcers induced by cysteamine or mepirizole in a dose-dependent manner: the ID50 values were 0.7, 2.4, 0.7, 8.5, 1.1 and 0.3 mg/kg, p.o. or i.d., respectively. Famotidine inhibited reflux esophagitis with an ID50 value of 12.9 mg/kg, but did not cause 50% inhibition of ethanol-induced gastric lesions even at 100 mg/kg, although it showed almost the same or a little stronger potency on other experimental ulcers: ID50 values were 0.3 -1.4 mg/kg. Significant aggravation of ethanol-or water-immersion stress-induced lesions was observed in rats given famotidine at 30 mg/kg twice daily for 4 days, but not in rats given AG-1749 at 10 mg/kg twice daily. Administration of AG-1749 for 14 consecutive days markedly accelerated the healing of acetic acid-induced gastric and duodenal ulcers, and the healing effect was significant at 10 and 30 mg/kg/day, p.o. Famotidine also accelerated the healing of ulcers, but its potency was less than that of AG-1749. The results of this study indicate that although AG-1749 is slightly less potent than famotidine in inhibiting acutely induced gastroduodenal lesions, this agent is superior to famotidine in promoting the healing of ulcers and in inhibiting reflux esophagitis and ethanol-induced gastric lesions.
There has been a marked improvement in the healing rate ever since histamine H2-receptor antagonists such as cimetidine, ranitidine and famotidine have been used for clinical treatment of peptic ulcers, and the histamine H2-receptor antagonists are now the therapeutic option of first choice for peptic ulcers. In some patients, however, ulcer healing is difficult or impossible to achieve with H2-receptor antagonists, and these patients are considered to have refractory ulcers (1) . Recent reports indicate that the proton pump inhibitor omeprazole is effective even for refractory gastric and duodenal ulcers (2, 3) and is of unprecedented efficacy in the healing of reflux esophagitis even in severe forms refractory to treatment with high doses of H2-receptor antagonists (4) . AG-1749 exerts strong antisecretory and antiulcer effects by inhibiting (H+ + K+)-ATPase in parietal cells. We have already reported that AG-1749 is more potent than omeprazole and ranitidine in terms of antiulcer activity (5) . This study was performed to clarify the differences in the antiulcer actions of proton pump inhibitors and H2-receptor antagonists; AG-1749 was used as the representative of the former type and famotidine, a more potent H2-receptor antagonist than ranitidine, was used as the representative of the latter type.
MATERIALS AND METHODS
Acute ulcers Seven-week old male Jcl:Sprague-Dawley rats weighing 190 -230 g were used. The rats were fasted for 24 hr before the experiments.
Reflux esophagitis: Under ether anesthesia, rats were laparotomized, and both the pylorus and the junction between the forestomach and corpus were ligated, according to the method of Goto and Kishi (6) . Drugs were given intraduodenally immediately after the ligation. Four hours later, the rats were sacrificed by CO2 asphyxiation. The gastroesophageal portion of the digestive tract was removed, and the lesions in the thoracic esophagus were examined and were graded according to the following criteria; Esophagitis index: 0 1 2 3 % Lesion area in thoracic esophagus: 0 1-25 26-50 51-75 4 > 75 or perforation For the histopathological study, the removed gastroesophageal portion was fixed in 10% formalin solution. The specimens were embedded in paraffin, and thin sections were made and then stained with hematoxylin eosin.
In experiments used to examine the effects of drugs on acid secretion in the pylorus and forestomach-ligated rats, the gastroesophageal portion was removed 2 hr after ligation, and the gastric contents were collected. The volume of gastric juice was measured, the acidity was determined by automatic titration (Radiometer TTA81) to pH 7.0 with 0.1 N NaOH, and the total acid output during the 2-hr period was calculated.
Water-immersion stress-induced gastric lesions: Water-immersion stress lesions were induced as described by Takagi and Okabe (7) . The rats were given the drugs orally 30 min before being placed in a stress cage and being vertically immersed to the xiphoid process in a water bath maintained at 23°C. Five hours later, each animal was taken out of its cage and sacrificed by CO2 asphyxiation. The stomach was removed, filled with 10 ml of 1% formalin solution, and then immersed in the same formalin solution for 10 min. The stomachs were opened along the greater curvature. The length (mm) of the individual lesions in the corpus was measured under a dissecting microscope, and the sum of the lengths of all lesions in each stomach was used as the lesion index. The same fixing and measuring procedures were used in the experiments described below.
Aspirin-induced gastric lesions: The experiment was performed as described by Okabe et al. (8) . The pylorus of each rat was ligated under ether anesthesia, and drugs were given intraduodenallly just after the ligation. Aspirin (200 mg/kg) was given orally 10 min after the pylorus ligation. The animals were sacrificed 5 hr later, and the stomachs were examined for lesions.
Ethanol-induced gastric lesions: Drugs were administered orally 30 min before 1 ml of absolute ethanol was administered orally. The animals were sacrificed 1 hr after receiving the ethanol. The stomachs were removed and examined for lesions.
Cysteamine-induced duodenal ulcers: Rats were given 400 mg/kg of cysteamine orally 30 min after oral administration of the test drugs. Eighteen hours later, 1 ml of a 0.5% Evans blue solution was injected into each rat, and the rats were then sacrificed. The gastroduodenal region was removed, and the area (mm2) of the duodenal ulcer was measured.
Mepirizole-induced duodenal ulcers: Drugs were given orally 30 min before subcutaneous administration of mepirizole (200 mg/kg). Twenty-four hours later, 1 ml of a 0.5% Evans blue solution was injected into each rat, and the rats were then sacrificed by C02 asphyxiation. The gastroduodenal region was removed and examined for ulcers.
Effect on the formation of ethanol-or waterimmersion stress-induced lesions after repeated administration of drugs: Drugs were given orally to rats twice daily (AM 9:30 and PM 4:30) for 3 days, and the last dose was administered in the morning on the 4th day. Rats were fasted for 24 hr the last day of administration or 1, 2 or 3 days after the last administration. The rats in each group were subjected to water-immersion stress after the 24 hr fast, and gastric lesions were examined 5 hr later. In another experiment, rats were fasted for 24 hr after the last administration, and gastric lesions were induced by oral administration of 1 ml of 40% ethanol.
Chronic ulcers
Acetic acid-induced gastric or duodenal ulcers: Seven-week old male Jcl:SD rats were used. The rats were anesthetized with ether and subjected to laparotomy through a midline incision. The gastroduodenal region was exposed, and gastric ulcers were induced by injecting 20,ul of 20% acetic acid solution into the subserosal layer at the junction of the anterior wall of the corpus and the antrum. Duodenal ulcers were induced by pouring glacial acetic acid (60 ,ul) into a mold, 6 mm in diameter, placed in close contact with the serosal surface of the duodenal wall and removing the acetic acid 20 sec later. Drugs were given once a day (AM 10:00) for 14 consecutive days beginning 2 days after the operation. As the duration of action of famotidine at 30 mg/kg with respect to inhibition of histamine-induced acid secretion in rats is almost equal to that of AG-1749 at 10 mg/kg (H. Nagaya et al., unpublished data), both drugs were given once daily and their effects were compared. The animals were sacrificed by C02 asphyxiation on the 16th day after the operation, and the gastroduodenal region was removed. The ulcerated area (mm2) was measured under a dissecting microscope with a 1-mm square grid eyepiece (X 10).
For the histopathological study, the removed gastroduodenal region was embedded in paraffin, consecutive thin sections were made from tissue obtained from the center of the ulcer, and the sections were stained with hematoxylin eosin, Azan or PAS. Color micrographs of specimens stained with Azan were made, and histomorphometric measurement was carried out using an IBAS-2000 (Carl Zeiss, West Germany) according to the method of Tabayashi (9) . The length of each of the following parameters which are depicted in Fig. 1 was measured: a) apparent defect in the mucosal layer, b) true defect in the mucosa, c) regeneration of the mucosal layer, d) distance of ruptured muscularis mucosa, e) distance of ruptured muscularais propria, f) thickness of the base of the ulcer, and g) thickness of the margin of the ulcer. Indexes representing the healing effect of the test agent were calculated on the basis of these values. The healing index (A) and the mucosal regeneration index (B) were calculated using the following equations: A = (1 -a/e) X 100 B = c/(b + c) X 100 The degree of collagen fiber proliferaton was assigned a score of 0, 20, 40, 60, 80 or 100, and these scores were used as the collagen fiber proliferation indexes (C). The mean of A, B and C was calculated to obtain the total healing index (D).
Drugs
The following drugs were used: Aspirin (Yoshitomi), cysteamine (Wako), and mepirizole (Daiichi Pharmaceuticals). AG-1749 and omeprazole were synthesized, and famotidine was extracted from Gaster® (Yamanouchi) and purified in the Chemistry Research Laboratories of our division. AG-1749, omeprazole and famotidine were suspended in a 5% gum arabic solution for p.o. or i.d. administration.
Statistical analysis
Results are shown as the mean ± S.E. The statistical significance of the differences among groups was determined by Dunnett's test. ID50 values were calculated from the dose-inhibition relationships by the method of least squares. Fiducial limits of the ID50 values were calculated according to Fieller's theorem (10). 
RESULTS

Reflux esophagitis
Erosion was observed in almost all areas of the thoracic esophagus 4 hr after the pylorus and forestomach ligation. Perforation was observed in about 10% of the rats. The esophagitis index in the control group was 3.4 ± 0.4 (n = 10). AG-1749 at 0.3 mg/kg or more significantly inhibited the reflux esophagitis in a dose-dependent manner, the ID50 value being 0.7 mg/kg, i.d. (Fig. 2) . Omeprazole inhibited reflux esophagitis at 10 mg/kg or more; the ID50 value was 13.7 mg/kg, i.d. Famotidine tended to inhibit reflux esophagitis at 3 mg/kg or more, and significant inhibition was observed at the dose of 30 mg/kg; the ID50 value was 12.9 mg/kg, i.d. (Fig. 2 ). The percent inhibition by 30 mg/kg of famotidine was 59%, which was less than the maximum inhibition caused by 10 mg/kg of AG-1749 or 30 mg/kg of omeprazole (Fig. 2) .
The histological study revealed extensive loss of mucosal epithelial cells, edema, lysis, hemorrhage and thrombosis in the lamina propria and lysis and hemorrhage in the muscle layer of the esophagus in rats given a 5% gum arabic solution (Table 1, Fig. 3 ). These changes were markedly inhibited by the treatment with 10 mg/kg of AG-1749 (Fig. 3) . Scores (0, 1, 2, 3, 4) represent no, slight, mild, moderate and severe, respectively. AG-1749 was given intraduodenally immediately after the pylorus and forestomach ligation. The rats were killed 4 hr after the ligation. and famotidine on total acid output in the pylorus and forestomach-ligated rats. Rats were sacrificed 2 hr after the pylorus and the forestomach ligation. Each point represents the percent inhibition for 5 or 6 rats. **: P < 0.01 vs. Contorol. Each point represents the percent inhibition for 12 rats. *: P < 0.05, * * . P < (1 (11 vc Cnntrnl The effect of AG-1749 and famotidine on gastric secretion in the pylorus and forestomach-ligated rats was examined. AG-1749 inhibited acid secretion in a dose-dependent manner, and a significant inhibition was observed at 3 and 10 mg/kg (Fig. 4) . Famotidine inhibited acid secretion at 3 mg/kg or more but not significantly.
Water-immersion stress-induced gastric lesions
Punctate or elongated lesions mainly in the glandular stomach were caused by waterimmersion stress. The lesion index in the control group was 20.0 ± 2.1 (mm; n = 12). AG-1749 and famoditine (1-30 mg/kg) inhibited the formation of water-immersion stress lesions; the ID50 values were 2.4 and 1.4 mg/kg, p.o., respectively (Fig. 5) . AG-1749 showed the maximum inhibition of 100%, whereas the maximum inhibition produced by famotidine did not exceed 78%.
Aspirin-induced gastric lesions
Multiple elongated lesions were produced in the glandular stomach by aspirin; the lesion index in the control group was 47.2 ± 10.1 (mm; n = 12). AG-1749 (0.3 -10 mg/kg, i.d.) and famotidine (0.1-3 mg/kg, i.d.) dosedependently inhibited these gastric lesions; the ID50 values were 0.7 and 0.6 mg/kg, i.d., respectively.
Ethanol-induced gastric lesions
In the control group, severe band-like mucosal lesions were observed in the glandular stomach. AG-1749 (1-10 mg/kg, p.o.) inhibited the formation of gastric lesions induced by absolute ethanol dose-dependently; the ID50 value was 8.5 mg/kg, p.o. (Fig. 6 ). Famotidine given orally at 100 mg/kg inhibited the ethanol-induced gastric lesions by only 38%.
Cysteamine-induced duodenal ulcers
Penetrating or severe ulcers in the proximal duodenum were caused by cysteamine; the ulcer index in the control group was 13.7 ± 3.2 (mm'; n = 12). AG-1749 (0.3-10 mg/kg, p.o.) and famotidine (0.1-10 mg/kg, p.o.) dose-dependently inhibited the ulcer formation caused by cysteamine with ID50 values of 1.1 and 0.5 mg/kg, p.o., respectively. Mepirizole-induced duodenal ulcers Two penetrating ulcers in the proximal duodenum were usually produced by mepirizole. AG-1749 (0.1-3 mg/kg, p.o) and famotidine (0.1-3 mg/kg, p.o.) dose-dependently inhibited the size of the mepirizole-induced duodenal ulcers; the ID50 values in both cases were 0.3 mg/kg, p.o. (Fig. 7) .
Effects of repeated administration of AG-1749 and famotidine on formation of ethanol-or water-immersion stress-induced gastric lesions
The gastric lesion indexes in the groups given a 5% gum arabic solution for 4 days and subjected to water-immersion stress 1, 2, 3 or 4 days after the last administration were almost the same. The lesion indexes in the famotidine-treated groups increased in a dosedependent manner when the animals were subjected to water-immersion stress the day after the last administration (Fig. 8) . On the other hand, in the groups treated with AG- 1749, the lesion index decreased in the high dosage group. In the groups treated with 30 mg/kg of famotidine twice daily, lesion formation was aggravated by 31 and 81% 1 and 2 days after the last administration, respectively. Although the aggravation 1 day after the last administration was not significant in this experiment, the aggravation 2 days after the last administration was (Fig. 9) . The lesion index was however almost the same as that in the control group 3 and 4 days after the last administration. In the groups treated with 10 mg/kg of AG-1749 for 4 days, significant aggravation was not observed 1, 2, 3 or 4 days after the last administration.
In another experiment, on the day after the last drug administration, 1 ml of 40% ethanol solution was administered orally to the rats treated with 10 mg/kg of AG-1749 or 30 mg/kg of famotidine for 4 days. The lesion indexes in the control, AG-1749 and famotidine group were 68.7 ± 11.6, 65.8 ± 7.2 and 117.8 ± 13.3 (mm; n = 12), respectively; and the Fig. 9 . Effects of 4 consecutive days of twice daily oral treatment with AG-1749 and famotidine on the formation of gastric lesions induced by water-immersion stress. Rats were subjected to water-immersion stress 1, 2, 3 or 4 days after 4-day administration of AG-1749 (10 mg/kg X 2/day) or famotidine (30 mg/kg X 2/day). Data are expressed as the percent increase in lesion index as compared to the control group which consisted of 12 rats-**: P < 0.01 vs_ Controllesion index in the famotidine group was significantly (P < 0.01) larger than that in the control group.
Acetic acid-induced gastric ulcers
Subserosal injection of 20% acetic acid produced a round ulcer in the stomach. AG-1749 (3-30 mg/kg/day, p.o.) given once daily accelerated the rate at which the ulcer size decreased (Figs. 10 and 11) . The curative effect of AG-1749 was marked and significant at 10 and 30 mg/kg/day. Famotidine (3 -100 mg/kg/day, p.o.) also accelerated the rate at 121 which the size of ulcer decreased, and its effect was significant at 100 mg/kg/day. Table 2 shows the results of histomorphometric measurement in the groups treated with 5% gum arabic, AG-1749 at 10 and 30 mg/kg/day and famotidine at 100 mg/kg/day. The diameter of the true defect in the mucosa, the distance of the ruptured lamina muscularis mucosa and the thickness of the base of the ulcer were significantly smaller in the group treated with AG-1749 (10 mg/kg/day) than in the control group. The healing index, the mucosal regenerating index and collagen fiber Fig. 10 . Effects of AG-1749 and famotidine on healing of acetic acid-induced gastric ulcers in rats. Drugs were given orally once daily for 14 days. Data are the mean values with S.E. for 7-11 rats. *: P < 0.05, **: P < 0 .01 vs. Control. Fig. 11 . Histological appearance of the acetic acid-induced gastric ulcer in a rat that received 5% gum arabic solution (A) or AG-1749 at 10 mg/kg once daily for 14 days (B). H.E. stain (X 24). The length of the defect in the mucosa and the thickness of the gastric ulcer were reduced by treatment with AG-1749. proliferation index tended to be greater, and the total healing index was significantly greater in the AG-1749 (10 mg/kg/day) group. In the group treated with 30 mg/kg/day of AG-1749, almost the same tendency was observed, but significant differences in histomorphometric measurements and healing indexes were not observed when a comparison was made with the control group. In the group treated with 100 mg/kg/day of famotidine, there were no significant changes in the histomorphometric regeneration index or the total healing index, but the collagen fiber proliferation index was significantly greater than that in the control group.
Acetic acid-induced duodenal ulcers
In the group treated with a 5% gum arabic solution for 14 days, a round ulcer was found in the duodenum. AG-1749 at 3, 10 and 30 mg/kg/day given once daily accelerated the rate at which the size of the ulcer decreased, and the curative effect was significant at 10 and 30 mg/kg/day (Fig. 12 ). Famotidine (3-100 mg/kg/day) also promoted healing, and a significant curative effect was observed at 10 and 100 mg/kg/day. Table 3 shows the results of histomorphometric measurement and the calculated healing indexes in the groups treated with 5% gum arabic solution, AG-1749 at 10 and 30 mg/kg/day and famotidine at 100 mg/kg/day. In the group treated with 10 mg/kg/day of AG-1749, values of the histomorphometric measurements were smaller than those in the control group, but significant differences were not observed. In the group treated with AG-1749 at 30 mg/kg/day, the true defect in the rats. *: P < 0.05, **: P < 0.01 vs. Control. mucosa, the distance of the ruptured lamina muscularis mucosa and the thickness of the base of the ulcer were significantly smaller; and the healing index, the mucosal regeneration index and the total healing index were significantly greater than those in the control group. In the group treated with famotidine at 100 mg/kg/day, there was a tendency toward improvement as seen by decreased histomorphometric measurements and greater healing indexes, but there were no significant differences when a comparison was made with the control group.
DISCUSSION
AG-1749 inhibited the appearance of reflux esophagitis and various gastric and duodenal ulcers in rats in a dose-dependent manner. As the formation of most gastric lesions and duodenal ulcers is inhibited by antisecretory agents, acid secretion is considered to be an important factor in their pathogenesis (11) . The ID50 values of AG-1749 for experimental ulcers with the exception of ethanol-induced gastric lesions were 0.3 -2.4 mg/kg; and the values are almost the same as the ID50 values (1.6 -6.0 mg/kg) for basal and histamine-or pentagastrin-stimulated acid secretion in rats (5, 12) . Famotidine also inhibited the formation of these ulcers, and the ID50 values were 0.3 -1.4 mg/kg. These values are almost the same as the antisecretory doses (ID50 values = 0 .3 -2.6 mg/kg) for basal and histamine-, pentagastrin-or bethanechol-stimulated acid secretion (12) . These results strongly suggest that the antiulcer effects of AG-1749 and famotidine can be ascribed mainly to their antisecretory activity.
Reflux esophagitis was easily produced in rats by ligating the pylorus and forestomach. AG-1749, omeprazole and famotidine inhibited the appearance of reflux esophagitis in rats in a dose-dependant manner, and AG-1749 was the most potent among the three; ID50 values were 0.7, 13.7 and 12.9 mg/kg, i.d., respectively. As reflux esophagitis is considered to be caused by a reflux of gastric acid, the potency of drugs seems to be related to their antisecretory activity. In our previous study (12) , the effects of AG-1749, omeprazole and famotidine on basal acid secretion were examined in pylorus-ligated rats, and famotidine was the most potent; the ID50 values were 3.6, 8.5 and 0.3 mg/kg, i, d. , respectively. These results are not in agreement with the above results related to the potencies of the three agents in reflux esophagitis. AG-1749 was much more potent than famotidine and was 20 times as potent as omeprazole in reflux esophagities. These findings indicate the possibilities that AG-1749 has a protective action on the esophagus or that the acid secretion in the pylorus and forestomach-ligated rats is different from that in the pylorusligated rats. Therefore, we studied the effects of AG-1749 and famotidine in inhibiting acid secretion in the pylorus and forestomachligated rats. The results indicated that AG-1749 was more potent than famotidine on acid secretion in the pylorus and forestomachligated rats. We have previously found that famotidine is less potent than AG-1749 in inhibition of 2-deoxy-D-glucose-stimulated or water-immersion stress-stimulated acid secretion, although famotidine is more potent than AG-1749 in inhibiting basal and histamine-, pentagastrin-or bethanechol-stimulated acid secretion in rats (12) , suggesting that famotidine is not potent in inhibiting acid secretion caused by nerve stimulation. These findings indicate that it is likely that vagus nerve-stimulated acid secretion is induced in the pylorus and forestomach-ligated rats; and therefore, the inhibitory activity of famotidine in reflux esophagitis is less potent than that of AG-1749. However, the involvement of mechanisms other than the inhibition of acid secretion cannot be excluded, as AG-1749 significantly inhibited reflux esophagitis at non-antisecretory doses (0.3 and 1 mg/kg), and this agent was far more potent than omprazole. Further study is necessary to clarify this.
Reflux esophagitis in patients is considered to be caused by several factors such as incompetence of the lower esophageal sphincter, inefficient esophageal clearance, the irritant effect of refluxed material and decreased acid resistance of the esophageal mucosa (13) . Failure of the antireflux defense mechanisms is responsible for gastric juice's refluxing into the esophagus and remaining in contact with the esophageal mucosa for a sufficient time to produce symptoms and cause inflammation. Therefore, mainly antisecretory drugs and prokinetic agents are used for the treatment of reflux esophagitis. Recent clinical data show that omeprazole is highly efficacious, particularly in the management of severe reflux esophagitis resistant to treatment with high doses of H2-receptor antagonists (4, 14) . Although there may be discrepancies between the results obtained in the rat model and clinical data, the high potency of AG-1749 with respect to inhibition of reflux esophagitis in rats indicates that this may be a pi-omising drug for the treatment of reflux esophagitis.
AG-1749 and famotidine inhibited waterimmersion stress-induced gastric lesions. Famotidine was more potent than AG-1749 when the ID50 values were compared, but the maximum inhibition caused by AG-1749 was greater than that caused by famotidine; AG-1749 showed a maximum inhibition of 100%, whereas complete inhibition was not obtained even with 30 mg/kg of famotidine. We found that AG-1749 potently inhibits the acid secretion induced in rats by water-immersion stress, but the inhibition caused by famotidine is moderate (12) . These findings suggest that although the formation of water-immersion stress-induced lesions is inhibited by moderate inhibition of acid secretion, strong inhibition of acid secretion is necessary for complete prevention of lesion formation.
Acid is generally considered to play a minor role in the pathogenesis of ethanol-induced gastric lesions, as the lesions are not inhibited by antisecretory agents or antacids (15) . In this study, the formation of ethanol-induced gastric lesions was not inhibited by 30 mg/kg of famotidine and was only slightly inhibited by 100 mg/kg of famotidine. Shiratsuchi et al. (16) also reported that famotidine did not inhibit the formation of ethanol-induced gastric lesions in rats, and we previously reported that cimetidine and ranitidine did not show significant inhibition of the formation of ethanol-induced gastric lesions (5, 17) . These results indicate that H2-receptor antagonists have only a weak protective action against the formation of ethanol-induced lesions. AG-1749 inhibited the formation of ethanol-induced gastric lesions at doses higher than the antisecretory doses. It has been reported that oral administration of omeprazole inhibits the formation of ethanol-induced gastric lesions in rats and that the biosynthesis of prostaglandins is not involved in its protective effect (18) . Additionally, we found that the protective effect of AG-1749 was not affected by pretreatment with indomethacin (N. Inatomi et al., unpublished data). Although the exact mechanisms of the protective action of proton pump inhibitors are not known, these agents with mucosal protective action are desirable in the treatment of peptic ulcers.
It has been reported that repeated administration of H2-receptor antagonists weakens gastric mucosasl defensive mechanism (19) . Thus, we repeatedly administered AG-1749 and examined the defensive mechanisms of the gastric mocosa. In the groups treated with famotidine for 4 days, aggravation of the lesion formation induced by water-immersion stress was observed 1 and 2 days after the last administration, and this effect was dosedependent. In contrast, significant aggravation was not observed in any of the groups treated with AG-1749. The formation of ethanolinduced gastric lesions was also significantly aggravated in the famotidine-treated group, but not in the AG-1749 group. It has been postulated that a persistent low acidic condition in the stomach is a causative factor for weakening of defensive mechanisms of the gastric mucosa induced by cimetidine (20) . However, since repeated administration of AG-1749 did not aggravate the gastric lesions induced by water-immersion stress or ethanol, the significant aggravation by H2-receptor antagonists cannot be explained by the above hypothesis.
We previously reported that the effects of AG-1749 on healing of acetic acid-induced gastric or duoodenal ulcers were marked, and that AG-1749 was more potent than omeprazole and ranitidine (5) . In this study, the curative effect of AG-1749 was reproducible, and its effect was confirmed histopathologically. Famotidine accelerated the rate at which the ulcer size decreased, but it was less potent than AG-1749. However, this apparent curative effect of famotidine was not observed histopathologically even at 100 mg/kg. Okabe and Nobuhara (21) reported that oral administration of famotidine at 60 mg/kg twice daily for 14 days did not accelerate the healing of gastric ulcers induced by 40 ,u 1 of 20% acetic acid but that at 200 mg/kg twice daily, the ulcer size was reduced by 22%. The results as to the curative effect of cimetidine are not consistent. Okabe et al. (22) reported that cimetidine at 100 mg/kg twice daily for 12 days significantly accelerated the healing of gastric ulcers induced by 15 ,ul of 20% acetic acid, but Yamamoto et al. (23) reported that cimetidine at 200 mg/kg twice daily for 14 days did not significantly promote the healing of ulcers induced by 25 ul of 20% acetic acid. These inconsistencies may be partly due to the differences in experimental conditions. Nonetheless, these results strongly suggest that a dose much higher than the antisecretory dose is required for H2-receptor antagonists to promote the healing of acetic acidinduced gastric ulcers and that the results obtained using acetic acid-induced gastric ulcers do not necessarily predict the efficacy of the agent in clinical studies. In contrast, AG-1749 significantly accelerated the healing of acetic acid-induced gastric ulcers at antisecretory doses. The following are considered to be the possible causes for the difference in curative doses of H2-receptor antagonists and AG-1749: 1) As AG-1749 inhibits all kinds of stimulated acid secetion, it is effective at antisecretory doses, 2) The mucosal protective effect of AG-1749 helps to promote the healing of ulcers, and 3) Gastrin release is stimulated by AG-1749 and H2-receptor antagonists, but the duration of gastrin release may be longer or the amount of gastrin released may be greater in the case of AG-1749 administration, resulting in more pronounced acceleration of the healing of ulcers due to the trophic effect of gastrin (24) . In the case of acetic acid-induced duodenal ulcers, famotidine at 10 mg/kg/day significantly accelerated the healing. The results suggest that inhibition of acid secretion greatly promotes the healing of duodenal ulcers.
In summary, AG-1749 was almost as potent as famotidine in inhibiting the formation of acutely induced gastric or duodenal ulcers and was much more potent than famotidine in inhibiting the appearance of reflux esophagitis and in healing of acetic acid-induced gastric and duodenal ulcers in rats.
